Education
About Us
Working with TipRanks
Follow Us
Madrigal (MDGL)
:MDGL
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$200.63 - $457.16
Previous CloseN/A
Volume47.78K
Average Volume (3M)414.87K
Market Cap
$9.49B
Enterprise Value$6.04B
Total Cash (Recent Filing)$802.02M
Total Debt (Recent Filing)$123.95M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Oct 30, 2025EPS Estimate
-1.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding22,289,015
10 Day Avg. Volume331,548
30 Day Avg. Volume414,866
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue11.72
Enterprise Value/Gross Profit12.21
Enterprise Value/Ebitda-22.65
Forecast
1Y Price Target
$476.67Price Target Upside12.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
European Market LaunchRezdiffra is now the first and only approved MASH therapy in Europe with labeling that does not specify a biopsy requirement for treatment.
Market ExpectationsThe EU is expected to be a meaningful growth driver in the years ahead for MDGL.
Sales PerformanceRezdiffra has more than 23,000 patients, indicating an acceleration in net patient additions, showcasing growing demand.
Bears Say
Competitive PressureSome investors are concerned about Rezdiffra losing market share to the more visible and popularized Wegovy treatment.
Growth ConcernsAnalysts believe the EU is unlikely to be a major growth driver for Madrigal, at least in the near term, due to slower European launch dynamics and pricing constraints.
Pricing And ReimbursementCost-conscious single payer systems in the EU may not reimburse Rezdiffra near its current annual Wholesale Acquisition Cost of approximately $49k.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $200.63 and its highest was $457.16 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $9.49B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Oct 30, 2025 which is in 43 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on Aug 05, 2025. The company reported -$1.9 earnings per share for the quarter, beating the consensus estimate of -$3.554 by $1.654.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -1.93.
How many shares outstanding does Madrigal have?
Madrigal has 22,289,015 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$1.9 in its last earnings report, beating expectations of -$3.554. Following the earnings report the stock price went up 8.587%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
Madrigal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$476.67 (12.00% Upside)
$476.67 (12.00% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 202.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $54.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.01%
12-Months-Change
Fundamentals
Return on Equity
-36.30%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead product candidate, resmetirom, is being evaluated for its potential to treat non-alcoholic steatohepatitis (NASH), a progressive liver disease. Madrigal Pharmaceuticals operates predominantly in the biotechnology and pharmaceuticals sector, leveraging cutting-edge research and development to address significant unmet medical needs.
MDGL Company Deck
MDGL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as strong revenue growth, patent extension, and international expansion plans. However, there were challenges like increased expenses and expected choppy gross to net dynamics. Overall, the positive developments and strategic advancements outweigh the challenges faced.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$476.67
▲(12.00% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
19.50% Insiders
25.31% Mutual Funds
<0.01% Other Institutional Investors
41.76% Public Companies and
Individual Investors